Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma

Singh, Dave; Szenes, Victoria; Eich, A.; Leaker, Brian; Badorrek, Philipp; Ignatenko, Stanislav; Koch, Annelize; Wilkes, Denisa; Shamp, Trisha; O. Aliprantis, Antonios; Amiri, Karima; Van Epps, Heather; Goyal, Lovely; Mayawala, Kapil; Robertson, Andrew; Straley, Stephanie; Prashad, Sacha; Snyder, Alexandra; Kornmann, Oliver

doi:10.1183/13993003.congress-2025.oa2332

Public

Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma

Published • Sep 27, 2025

Authors:

Dave Singh

Victoria Szenes

A. Eich

Abstract

Background: Thymic stromal lymphopoietin (TSLP) is a validated therapeutic target in asthma. GB-0895 is a next-generation, subcutaneously administered anti-TSLP monoclonal antibody with ~20-fold higher affinity for TSLP compared to tezepelumab and YTE Fc modifications for extended half-life. Aims: T...

Subject

Medicine

Dosing

Thymic stromal lymphopoietin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!